In the past decades, the development of EGFR-TKIs brought tremendous benefits to NSCLC patients as they could extend PFS and OS while having less adverse effects compared to traditional chemotherapy and radiotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.